Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: 5,17,37,5,101,... who wrote (356)	3/10/1999 10:40:00 AM
From: QuietWon	Read Replies (1) \| Respond to of 2515

Jacksom, you're a doctor, right? The comparison to Genetech I think shows IMCL is using a similar methodology to Genetech, but does so on different areas of the body. I don't think they will comptete, at least not in the near term (year or two). Just my opinion. Your medical expertise and exact difference in the techniques would be appreciated by me and others I'm sure.

To: 5,17,37,5,101,... who wrote (356)	3/10/1999 12:54:00 PM
From: Greg Rich	Read Replies (1) \| Respond to of 2515

Did you guys notice who the analyst was at Moors and Cabot? It is Jim McCamant who writes the Medical Technology Stock Letter and has had a price target of $30/share for at least the past year that I have been a subscriber and I believe long before that. I like McCamant and the letter, but his recommendation and stock price has been around for some time. Hope that this new publicity does the trick though. I'm in for the long haul. Greg